AstraZeneca to complete its direct listing of ordinary shares and US debt securities on the New York Stock Exchange

AstraZeneca has recently provided their notice of the voluntary withdrawal from listing on The Nasdaq Stock Market LLC  of  its American Depositary Shares, representing AstraZeneca’s ordinary shares of $0.25 each on a two-for-one basis and debt securities issued by AstraZeneca or its wholly-owned subsidiary AstraZeneca Finance LLC and guaranteed by AstraZeneca. As previously announced on 29 September 2025, AstraZeneca plans to complete a direct listing of its Ordinary Shares and the Debt Securities on the NYSE, which will be effective after market close on 30 January 2026. The direct listing is a part of AstraZeneca’s shareholder approved plan to harmonise its share listing structure to deliver a global listing for global investors in a global company. Following implementation of the Harmonised Listing Structure, shareholders will be able to trade their interests in the Ordinary Shares across the London Stock Exchange, Nasdaq Stockholm and the NYSE.

 

---

---

Related Topics and Keywords

AstraZeneca, US debt securities